Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen. セルメディシン株式会社が紹介する自家がんワクチン療法に関する記事や、論文をご覧いただけます。

会社情報

紹介記事・論文

Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen.

Authors:Kim CH, Todoroki T, Matsumura M, Ohno T.

Journal:J Cancer Res Clin Oncol. 2000 Jul;126(7):383-90.

Abstract:The inducibility of cytotoxic T lymphocytes (CTL) that react with carcinoembryonic antigen (CEA) was tested in cancer patients with elevated (more than 5 ng/ml) serum CEA levels when antigen presentation was carried out with paraformaldehyde-fixed adhesive peripheral blood mononuclear cells (PBMC) from the patient that had been pre-loaded with CEA652(9), an HLA-A2402-restricted tumor antigenic peptide derived from CEA. By culturing fresh autologous PBMC on the fixed cell layer in medium containing interleukin-1, -2, -4 and -6. three out of eight patients developed CTL. The CTL from two of these patients killed CEA-protein-producing gastric cancer cells carrying HLA-A2402 and the cells from the remaining patient killed CEA-non-producing stomach cancer cells pre-loaded with CEA652(9). The results suggest that a single antigenic peptide on the fixed adhesive cells will allow the ex vivo induction of peptide-reactive CTL that are easier to handle and allow antigen presentation without tedious preculture of the "professional" antigen-presenting dendritic-cells.

注:弊社は病院やクリニックではなくバイオ企業であるため、症例報告や論文内容のWeb掲載は許容されています。

ご相談は無料です。
お気軽にお問い合わせください。